Prognostic and predictive value of IPSS-R in assessing overall survival (OS) in a phase III study of rigosertib in second-line higher-risk (HR) MDS patients.
暂无分享，去创建一个
R. Collins | P. Greenberg | G. Gaidano | G. Garcia-Manero | D. Steensma | P. Fenaux | K. Kreuzer | M. Sekeres | G. Roboz | U. Platzbecker | M. Baer | L. Godley | N. Azarnia | A. Al-Kali | B. Scott | L. Silverman | E. Atallah